Trial Profile
A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 13 Nov 2023
Price :
$35
*
At a glance
- Drugs Cetrelimab (Primary) ; Cetrelimab (Primary)
- Indications Bladder cancer; Colorectal cancer; Gastric cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Renal cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors Janssen Research & Development; Janssen-Cilag
- 07 Nov 2023 Planned primary completion date changed from 24 Oct 2023 to 16 Nov 2023.
- 12 Sep 2023 Planned primary completion date changed from 18 Oct 2024 to 24 Oct 2023.
- 12 Sep 2023 Planned number of patients changed from 600 to 609.